Watanabe et al., 2023 - Google Patents
Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignanciesWatanabe et al., 2023
View HTML- Document ID
- 8320040654445577643
- Author
- Watanabe N
- Mo F
- Zheng R
- Ma R
- Bray V
- van Leeuwen D
- Sritabal-Ramirez J
- Hu H
- Wang S
- Mehta B
- Srinivasan M
- Scherer L
- Zhang H
- Thakkar S
- Hill L
- Heslop H
- Cheng C
- Brenner M
- Mamonkin M
- Publication year
- Publication venue
- Molecular Therapy
External Links
Snippet
Chimeric antigen receptor (CAR)-mediated targeting of T lineage antigens for the therapy of blood malignancies is frequently complicated by self-targeting of CAR T cells or their excessive differentiation driven by constant CAR signaling. Expression of CARs targeting …
- 210000001744 T-Lymphocytes 0 title abstract description 243
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Watanabe et al. | Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies | |
| Dawson et al. | Functional effects of chimeric antigen receptor co-receptor signaling domains in human regulatory T cells | |
| Lanitis et al. | Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression | |
| Fan et al. | Differential roles of IL-2 signaling in developing versus mature Tregs | |
| Kim et al. | Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia | |
| Chapuis et al. | Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients | |
| Zhang et al. | A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity | |
| Yi et al. | Optimizing EphA2-CAR T cells for the adoptive immunotherapy of glioma | |
| Brown et al. | Optimization of IL13Rα2-targeted chimeric antigen receptor T cells for improved anti-tumor efficacy against glioblastoma | |
| Panjwani et al. | Feasibility and safety of RNA-transfected CD20-specific chimeric antigen receptor T cells in dogs with spontaneous B cell lymphoma | |
| Morita et al. | Enhanced expression of anti-CD19 chimeric antigen receptor in piggyBac transposon-engineered T cells | |
| US10738278B2 (en) | Engineered cells for adoptive cell therapy | |
| Theisen et al. | Batf3-dependent genes control tumor rejection induced by dendritic cells independently of cross-presentation | |
| Rosenberg et al. | Adoptive cell transfer as personalized immunotherapy for human cancer | |
| Kim et al. | Distinct dendritic cell subsets dictate the fate decision between effector and memory CD8+ T cell differentiation by a CD24-dependent mechanism | |
| Velardi et al. | Sex steroid blockade enhances thymopoiesis by modulating Notch signaling | |
| Huang et al. | Sleeping Beauty transposon‐mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies | |
| Heemskerk et al. | Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex | |
| Huye et al. | Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination | |
| Bose et al. | Tumor-derived vascular pericytes anergize Th cells | |
| Davila et al. | Cell-based immunotherapy with suppressor CD8+ T cells in rheumatoid arthritis | |
| JP2023179469A (en) | Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy | |
| TW201928052A (en) | Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof | |
| Chen et al. | Bifunctional cancer cell–based vaccine concomitantly drives direct tumor killing and antitumor immunity | |
| Sahin et al. | Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma |